Cocrystal Pharma Announces In Vitro Studies Showing COVID-19 Oral And Intranasal/Pulmonary Protease Inhibitors Exhibit Antiviral Activity Against SARS-CoV-2, Including Omicron, Delta, Alpha, Beta And Gamma Variants